Ranok Therapeutics, Pfizer team up on targeted protein degradation

By The Science Advisory Board staff writers

November 30, 2021 -- Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation (CHAMP) platform technology on an undisclosed cancer target.

CHAMP takes advantage of the cellular chaperone network, which could potentially improve the technology's safety and efficacy due to the selective targeting of tumors versus other targeted protein degradation approaches, Ranok said.

Ranok received $40 million in series B financing in August 2021.

Financial details of the agreement were not disclosed.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?